Compare · INSP vs WST
INSP vs WST
Side-by-side comparison of Inspire Medical Systems Inc. (INSP) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSP and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 13.9x INSP ($1.77B).
- Over the past year, INSP is down 33.3% and WST is up 42.5% - WST leads by 75.9 points.
- INSP has been more active in the news (8 items in the past 4 weeks vs 1 for WST).
- INSP has more recent analyst coverage (25 ratings vs 18 for WST).
- Company
- Inspire Medical Systems Inc.
- West Pharmaceutical Services Inc.
- Price
- $61.13-0.49%
- $348.50-1.36%
- Market cap
- $1.77B
- $24.52B
- 1M return
- +19.89%
- +5.23%
- 1Y return
- -33.34%
- +42.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 1
- Recent ratings
- 25
- 18
Inspire Medical Systems Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest INSP
- SEC Form SCHEDULE 13G filed by Inspire Medical Systems Inc.
- Officer Kelly Jason P sold $57,347 worth of shares (963 units at $59.55), decreasing direct ownership by 5% to 18,985 units (SEC Form 4)
- Chief People Officer Mann Melissa covered exercise/tax liability with 652 shares, decreasing direct ownership by 3% to 22,957 units (SEC Form 4) to satisfy withholding tax
- Inspire Medical Systems upgraded by Oppenheimer with a new price target
- SEC Form 10-Q filed by Inspire Medical Systems Inc.
- Mobia Medical Appoints Myriam Curet, M.D., to its Board of Directors
- Inspire Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
- UBS resumed coverage on Inspire Medical Systems with a new price target
- Director Carrel Michael H was granted 5,631 shares (SEC Form 4)
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target